BioCentury | May 2, 2019
Emerging Company Profile

SAB: Human polyclonal antibodies on the hoof

SAB’s platform for producing human polyclonal antibodies directly in cows and goats avoids the limitations of other methods that start from animal or donor-derived antibodies. Therapeutic mAbs and bi- and tri-specific antibodies target no more...
BioCentury | Sep 29, 2014
Clinical News

AVI-7537 regulatory update

...EMA said it has identified the following therapies: BCX4430 from BioCryst; hyperimmune horse sera from Fab'entech...
...nanoparticle (LNP) technology -- is in Phase I testing. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), Durham, N.C. Fab'entech...
BioCentury | Sep 26, 2014
Politics & Policy

CHMP to review Ebola treatments

...of Fujifilm Holdings Corp. (Tokyo:4901) and MediVector Inc. (Boston, Mass.); and Hyperimmune horse sera from Fab'entech...
Items per page:
1 - 3 of 3
BioCentury | May 2, 2019
Emerging Company Profile

SAB: Human polyclonal antibodies on the hoof

SAB’s platform for producing human polyclonal antibodies directly in cows and goats avoids the limitations of other methods that start from animal or donor-derived antibodies. Therapeutic mAbs and bi- and tri-specific antibodies target no more...
BioCentury | Sep 29, 2014
Clinical News

AVI-7537 regulatory update

...EMA said it has identified the following therapies: BCX4430 from BioCryst; hyperimmune horse sera from Fab'entech...
...nanoparticle (LNP) technology -- is in Phase I testing. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), Durham, N.C. Fab'entech...
BioCentury | Sep 26, 2014
Politics & Policy

CHMP to review Ebola treatments

...of Fujifilm Holdings Corp. (Tokyo:4901) and MediVector Inc. (Boston, Mass.); and Hyperimmune horse sera from Fab'entech...
Items per page:
1 - 3 of 3